Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)

- Company to present Phase 1 data from its lead program, MDK-703, an Interleukin-7 (IL-7) mimetic with an extended half-life
- Additional poster showcases preclinical proof-of-concept data characterizing MDK-1654, a differentiated synthetic peptide that is both an IL-7 receptor and non-alpha IL-2/15 receptor agonist

MENLO PARK, Calif., October 5, 2022 /PRNewswire/ -- Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE™ technology, announced today that it will deliver two poster presentations at the upcoming Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), taking place virtually and in Boston on November 8-12.

The first poster presentation will highlight preliminary Phase 1 safety, tolerability, and pharmacokinetic/pharmacodynamic data on Medikine’s lead program, MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikine’s innovative platform technology. A second poster will detail preclinical data on MDK-1654, Medikine’s dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINES.

Details on the poster presentations are as follows:

**Title:** A Phase 1 Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of MDK-703, an IL-7 Mimetic With Extended Half-life

- **Abstract #:** 625
- **Presenter:** Ron Barrett, PhD, Medikine
- **Date/Time:** Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST

**Title:** MDK1654: A Branched Synthetic Peptide that Activates Both the IL-7 Receptor and the βγc Form of the IL-2/15 Receptor

- **Abstract #:** 1097
- **Presenter:** Angie Park, PhD, Medikine
- **Date/Time:** Thursday, November 10, 2022, from 9:00 a.m. to 9:00 p.m. EST
Full abstracts will be made available online and will be included in the *Journal for ImmunoTherapy of Cancer (JITC)* supplement on November 7. Posters will also be available on the Medikine website at [www.Medikine.com](http://www.Medikine.com) following the poster presentations.

**ABOUT MEDIKINE**

Medikine is a biopharmaceutical company with a mission to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular “PEPTIKINES”- peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. These PEPTIKINES are engineered for low immunogenicity and are readily amenable to the incorporation of targeting and other pharmacological features.

Medikine’s lead candidate, MDK-703, currently in a Phase 1 clinical trial in healthy volunteers, is an IL-7 PEPTIKINE fused to an immunoglobulin Fc-domain. MDK-703 emulates the beneficial properties of IL-7, a cytokine critical for maintenance of T cell responses.

For more information, please visit [www.medikine.com](http://www.medikine.com).

**MEDIA CONTACT:**
Dan Boyle  
The Grace Communication Group  
dan@gracegroup.us  
(818) 209-1692

**INVESTOR CONTACT:**  
investors@medikine.com